Advances in Immunotherapy for Cancer: From Monoclonal Antibodies to CAR-T Cells

Immunotherapy has revolutionized cancer treatment by harnessing the body’s immune system to recognize and eradicate malignant cells. This paper provides a comprehensive review of the latest advances in cancer immunotherapy, from conventional monoclonal antibodies to novel cellular therapies such as chimeric antigen receptor T-cells (CAR-T). Monoclonal antibodies, including immune checkpoint inhibitors, have demonstrated significant efficacy across various cancers by targeting specific tumor antigens and modulating immune responses. Emerging strategies, such as CAR-T and other adoptive cell therapies, offer personalized approaches capable of achieving durable remissions in hematologic malignancies and are increasingly being explored in solid tumors. The paper also discusses combination therapies, biomarkers for predicting response, mechanisms of resistance, and strategies to mitigate therapy-related toxicities. By integrating preclinical findings, clinical trial outcomes, and translational research, this study highlights the current landscape, challenges, and future directions of immunotherapy. The review emphasizes the potential of immunotherapy to transform oncology practice, offering hope for improved patient survival and quality of life.